4 publishers · first seen Thu, 29 Oct 2026 06:58 UTC · updated Thu, 29 Oct 2026 20:06 UTC
The National Pharmaceutical Pricing Authority (NPPA) has revised the maximum retail prices of 643 cancer drug brands, with price reductions of up to 93.3% on some multi-brand medicines like palbociclib and pertuzumab, while 158 brands, including 72 single-source drugs, remain unchanged. The price of osimertinib (Tagrisso) stays at ₹1,37,893 for 10 tablets of 40 mg and ₹4,16,492.48 for 30 tablets of 80 mg, pembrolizumab (Keytruda) at ₹2,16,500 for a 100 mg vial, and selumetinib (Koselugo) at ₹10,21,992 for the 25 mg pack.
The NPPA's move follows a cap on trade margins at 30% for 137 non-scheduled anti-cancer medicines, expected to reduce prices by up to 70%, but the revised list shows most patented drugs retain their original prices. Only Hervycta, a pertuzumab and trastuzumab combination, saw a single-source price drop of about 49%, from ₹6,093.75 to ₹3,105.53. Patient savings are estimated at ₹2,500 crore to ₹3,500 crore annually, mainly from multi-brand targeted therapies now available as generics.
Content auto-generated. May contain inaccuracies.